Safety of droperidol in behavioural emergencies

Expert Opinion on Drug Safety

Volumn 3, Issue 4, 2004, Pages 369-378

  Shale, John H ^a   Shale, Christopher M ^b   Mastin, William D ^c  

^a San Diego County EMS   (United States)

^b Marine Corps Base   (United States)

^c Mental Health America of San Diego County   (United States)

Author keywords

Droperidol; Dysrhythmia; QTc interval; Sudden death; Torsades de pointes (TdP)

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BUTYROPHENONE; CHLORPROMAZINE; DIGOXIN; DIURETIC AGENT; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; KETOCONAZOLE; LITHIUM; LORAZEPAM; MACROLIDE; MESORIDAZINE; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; PIMOZIDE; PROCHLORPERAZINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TERFENADINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AGITATION; ATRIOVENTRICULAR BLOCK; BEHAVIOR DISORDER; CARDIOTOXICITY; CLINICAL STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG USE; EMERGENCY TREATMENT; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MEDICAL LITERATURE; MENTAL DISEASE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; QT PROLONGATION; RETINOPATHY; REVIEW; STANDARD; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; THEORY; TORSADE DES POINTES; UNITED STATES; VIOLENCE;

ADJUVANTS, ANESTHESIA; ANTIPSYCHOTIC AGENTS; DROPERIDOL; DRUG LABELING; EMERGENCY SERVICES, PSYCHIATRIC; EMERGENCY TREATMENT; HUMANS; LONG QT SYNDROME; PSYCHOMOTOR AGITATION; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 3543072194     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.4.369     Document Type: Review

References (78)

1. ALLEN MH, CURRIER GW, HUGHES DH, DOCHERTY JP, CARPENTER D, ROSS R: Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J. Psychiatr. Practice (2003) 9:16-38.
2. SHALE JH, SHALE CM, MASTIN WD: A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. J. Clin. Psychiatry (2003) 64:500-505.
3. VAN HARTEN PN, VAN TRIER JC, HORWITZ EH, MATROOS GE, HOEK HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J. Clin. Psychiatry (1998) 59:128-130.
4. CHI J: Beware these drugs: they're linked to sudden death. Drug Topics (2000) 145:42-45.
5. GLASSMAN AH, BIGGER JT Jr: Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death. Am. J. Psychiatry (2001) 158:1774-1782.
6. RODEN DM: A practical approach to torsade de pointes. Clin. Cardiol. (1997) 20:285-290.
7. THOMAS SH: Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React. Toxicol. Rev. (1994) 13:77-102.
8. DUBUSKE LM: Second-generation antihistamines: the risk of ventricular arrhythmias. Clin. Ther. (1999) 21:281-295.
9. WITCHEL HJ, HANCOX JC: Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol. (2000) 27:753-766.
10. DESSERTENNE F: Ventricular tachycardia with two variable opposing foci. Arch. Mal. Coeur Vaiss. (1966) 59:263-272.
11. YAP YG, GAMM J: Risk of torsade de pointes with non-cardiac drugs. Br. Med. J. (2000) 320:1158-1159.
12. DESSERTENNE F, COUMEL P, FABIATO A: Ventricular fibrillation and twisted peaks. Presse Med. (1969) 77:193-196.
13. LIBERATORE MA, ROBINSON DS: Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? J. Clin. Psychopharmacol. (1984) 4: 143-146.
14. FAYEK M, KINGSBURY SI, JAAFAR Z et al.: Cardiac effects of antipsychotic medications. Psychiatr. Serv. (2001) 52:607-609.
15. BUCKLEY NA, SANDERS P: Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. (2000) 23:215-228.
16. DROLET B, ZHANY S, DESKENES D et al.: Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol (1999) 10:1597-1604.
17. MONAHAN BP, FERGUSON CL, KILLEAVY ES et al.: Torsade de pointes occurring in association with terfenadine use. JAAM (1990) 264:2788-2790.
18. MOSS AJ: The QT interval and torsade de pointes. Drug Saf. (1999) 21 (Suppl. 1):5-10.
19. WOOLSEY RL, CHEN Y, FREIMAN JP, GILLIS RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 269:1532-1536.
20. RODEN DM: Torsade de pointes. Clin. Cardiol. (1993) 16:683-686.
21. MOSS AJ: Correct the QT interval correctly: QTc should be expressed in the same unit as the QT interval. Pacing Clin. Electrophysiol. (1996) 19:881-882.
22. MORGANROTH J, BROZOVICH FV, MCDONALD JT et al.: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am. J. Cardiol. (1991) 67:774-776.
23. PRAT CM, RUBERG S, MORGANROTH J et al.: Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am. Heart J. (1996) 131:472-480.
24. MOLNAR J, ZHANG F, WEISS J et al.: Diurnal pattern of the QTc interval; how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J. Am. Coll. Cardiol. (1996) 27:76-83.
25. NAGY D, DEMEERSMAN R, GALLAGHER D et al.: QTc interval (cardiac repolarization): lengthening after meals. Obes. Res. (1997) 5:531-537.
26. COMMITEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINES: The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Points to Consider: the Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Product. May (1996).
27. CARELLA MJ, MANTZ SL, ROVNER DR et al.: Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int. J. Obes. Relat. Metab. Disord. (1996) 20:938-942.
28. EL-GAMAL A, GALLAGHER D, NAWRAS A et al.: Effects of obesity on QT, RR, and QTc intervals. Am. J. Cardiol. (1995) 75:956-959.
29. NO AUTHORS LISTED: Geodon®, ziprasidone hydochloride, Package Insert.
30. BEDNAR MM, HARRIGAN EP, ANZIOANO RJ et al.: The QT interval. Prog. Cardiovasc. Dis. (2001) 43(5 Suppl. 1):1-45.
31. LAWRENCE KR, NASRAWAY SA: Conduction disturbances associated with administration of butyrophenene antipsychotics in the critically ill: a review of the literature. Pharmacotherapy (1997) 17:531-537.
32. NO AUTHORS LISTED: Working group of the Royal College of Psychiatrist Psychopharmacology Sub-Group. The association between antipsychotic drugs and sudden death [CR57]. Council report London: Royal college of Psychiatrists (1997).
33. NO AUTHORS LISTED: American Psychiatric Association Task Force Report 27. Sudden death in psychiatric patients: the role of neuroleptic drugs. Washington D.C. American Psychiatric Association (1987).
34. BUCKLEY NA, WHYTE IM, DAWSEN AH: Cardiotoxicity more common in thioridozine overdose than with other neuroleptics. J. Clin. Toxicol. (1995) 33:199-204.
35. HADDAD PM, ANDERSON IM: Antipsychotic-related arrhythmias. Drugs (2002) 62(11):1649-1670.
36. DEPONTI F, POLUZZI E, CAVILLI A et al.: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes: an overview. Drug Saf. (2002) 25(4):263-286.
37. MICHALETS EL, SMITH LK, VAN TASSEL ED: Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann. Pharmacother. (1998) 32:761-765.
38. KELLY HG, FAY JE, LAVERTY SG: Thioridazine HCL (Mellaril), its effect on the electrocardiogram and report of two fatalities with electrocardiographic abnormalities. Can. Med. Assoc. J. (1963) 89:546-553.
39. HAGOPIAN V, STRATTON DB, BUSIEK RD: Five cases of pigmentary retinopathy associated with thioridazine administration. Am. J. Pychiatry (1966) 123:97-100.
40. CAMPBELL JM, GRALNICK A: Pigmentary retinopathy associated with thioridazine administration. Behav. Neuropsychiatry (1971) 3:14.
41. FOWLER NO, MCCALL D, CHOU TC, HOLMES JC, HANENSON IB: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am. J. Cardiol. (1976) 37:223-230.
42. FAYER SA: Torsades de pointes ventricular tachyarrhythmia associated with haloperidol (letter). J. Clin. Psychopharmacol. (1986) 6:375-376.
43. WILT JL, MINNEMA AM, JOHNSEN RF et al.: Torsades de pointes associated with the intravenous use of haloperidol. Ann. Intern. Med. (1993) 119:391-394.
44. METZGER E, FRIEDMAN R: Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J. Clin. Psychopharmacol. (1993) 13:128-132.
45. HUNT N, STERN T: The association between intravenous haloperidol and torsades de pointes. Three cases and a literature review. Psychosomatics (1995) 36:541-549.
46. SHARMA ND, ROSMAN HS, PAHDI D et al.: Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiol. (1998) 81:238-240.
47. PERRAULT LP, DENAULT AY, CARRIER M et al.: Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can. J. Anesth. (2000) 47:251-254.
48. O'BRIEN JM, ROCKWOOD RP, SUH KI: Haloperidol induced torsades de pointes. Ann. Pharmocother. (1999) 33:1046-1050.
49. DISALVO TG, O'GARA PT: Torsades de pointes caused by high dose intravenous haloperidol in cardiac patients. Clin. Cardiol. (1995) 18:285-290.
50. HENDERSON RA, LANE S, HENRY JA: Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum. Exp. Toxicol. (1991) 10:59-62.
51. JACKSON T, DITMANSEN L, PHIBBS B: Torsades de pointes and low dose oral haloperidol. Arch. Intern. Med. (1997) 157:2013-2015.
52. KRIWISKY M, PERRY CY, TARCHITSKY D et al.: Haloperidol induced torsades de pointes. Chest (1990) 98:482-484.
53. MEHTONEN OP, ARANKO K, MALKONEN L, VAPAATALO H: A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr. Scand. (1991) 8:58-64.
54. BOBON J, BOBON DP, BREULET M et al.: Emergency treatment of agitation: droperidol. Acta Neurol. Psychiatr. Belg. (1968) 68:103-115.
55. MORRISON JD, CLARKE RS, DUNDEE JW: Studies of drugs given before anaesthesia XXI: Droperidol. Br. J. Anarsth. (1970) 42:730-735.
56. NEFF KE, DENNY D, BLACKLY PH: Control of severe agitation with droperidol. Dis. Nerv. Syst. (1972) 33:594-597.
57. GRANACHER RP, RUTH DD: Droperidol in acute agitation. Curr. Ther. Res. Clin. Exp. (1992) 25:361-365.
58. FLOCKHART DA, DRICI MD, KERBUSCH T et al.: Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J. Clin. Psychopharmacol. (2000) 20:317-324.
59. LANDE G, DROUIN E, GAUTHEIR C et al.: Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation. Ann. Fr. Anesth. Reanim. (1992) 11:629-635.
60. LEEUVAN AM, UDDERS J, STERKMANS P: Droperidol. In acutely agitated patients. J. Nerv. Ment. Dis. (1997) 164:280-283.
61. HOOPER JF, MINTER P: Droperidol in the management of psychiatric emergencies. J. Clin. Psychopharmacol. (1983) 3:262-263.
62. THOMAS H, SCHWARTZ E, PETRILLI R: Droperidol versus haloperidol for clinical restraint of agitated and combative patients. Ann. Emerg. Med. (1992) 21:407-413.
63. CHAMBERS RA, DRUSS BG: Droperidol: efficacy and side effects in psychiatric emergencies. J. Clin. Psychiatry (1999) 60:664-667.
64. RICHARDS JR, DERLET RW, DUNCAN DK: Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J. Emerg. Med. (1998) 16:567-573.
65. RESNICK M, BURTON BT: Droperidol versus haloperidol in the initial management of acutely agitated patients. J. Clin. Psychiatry (1984) 45:298-299.
66. SZUBA MP, BERGMAN KS, GUZE BH et al.: Safety and efficacy of high-dose droperidol in agitated patients. J. Clin. Psychopharmacol. (1992) 12:144-146.
67. FRYE MA, COURDREAUT MF, HAKEMAN SM et al.: Continuous droperidol infusion for management of agitated delirium in an intensive care unit. Psychosomatics (1995) 36:301-305.
68. NO AUTHORS LISTED: ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Health Syst. Pharm. (1999) 56:729-764.
69. REILLEY JG, AYIS SA, FERRIER SI, THOMAS SH: QT interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 355:1048-1052.
70. GURY C, CANCEIL O, IARIA P: Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale (2000) 26:62-72.
71. GUY JM, ANDRE-FOULT X, PORTE J et al.: Torsade de pointes longement de la duree de l'intervale QT apres injection de droperidol. Ann. Cardiol, Angeiol. (1991) 40:541-545.
72. BROWN M, LIBERTHSEN RR, ALI HH et al.: Perioperative anesthetic management of a patient with long QT syndrome (LQTS). Anesthesiology (1981) 55:586-589.
73. GESSMAN WA, PLOSTNIEKS J, JOHNSEN PC: Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. Anesthesiology (1973) 4:363-369.
74. LISCLKE V, BEHNE M, DOELKEN P et al.: Droperidol causes a dose dependent prolongation of the QT interval. Anesth. Analg. (1994) 79:983-986.
75. LASSER KE, ALLEN PD, WOOLHANDLER SJ, HIMMELSTEIN DU, WOLFE SM, BOR DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA (2002) 287(17):2215-2220.
76. KAO LW, KIRK MA, EVERS SJ, ROSENFELD SH: Droperidol, QT prolongation and sudden death: what is the evidence? Ann. Emerg. Med. (2003) 41(4):547-556.
77. HOROWITZ BZ, BIZOVI K, MORENO R: Droperidol - behind the black box warning. Acad. Emerg. Med. (2002) 9(6):615-618.
78. TIMELL AM: Thioridazine: re-evaluating the risk/benefit equation. Ann. Clin. Psychiatry (2000) 12:147-151. Abstract.